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Background—In pulmonary arterial hypertension (PH), sympathetic adrenergic activity is highly elevated. Sympathetic
overactivity is a compensatory mechanism at first, but might be detrimental for cardiac function in the long run. We
therefore investigated whether chronic low-dose treatment with bisoprolol (a cardioselective -blocker) has beneficial
effects on cardiac function in experimental PH.
Methods and Results—PH was induced in rats by a single injection of monocrotaline (60 mg/kg). Pressure telemetry in
PH rats revealed that 10 mg/kg bisoprolol was the lowest dose that blunted heart rate response during daily activity. Ten
days after monocrotaline injection, echocardiography was performed and PH rats were randomized for bisoprolol
treatment (oral gavage) or vehicle (n7/group). At end of study (body mass loss5%), echocardiography was repeated,
with additional pressure-volume measurements and histomolecular analyses. Compared with control, right ventricular
(RV) systolic pressure and arterial elastance (measure of vascular resistance) more than tripled in PH. Bisoprolol
delayed time to right heart failure (P0.05). RV afterload was unaffected, however, bisoprolol treatment increased RV
contractility and filling (both P0.01), and partially restored right ventriculo-arterial coupling and cardiac output (both
P0.05). Bisoprolol restored RV -adrenergic receptor signaling. Histology revealed significantly less RV fibrosis and
myocardial inflammation in bisoprolol treated PH rats.
Conclusions—In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially
preserves RV systolic and diastolic function. These promising results suggest a therapeutic role for -blockers in PH
that warrants further clinical investigation. (Circ Heart Fail. 2012;5:97-105.)
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Pulmonary arterial hypertension (PH) is a fatal disease,characterized by progressive vascular remodeling and in-
creased right ventricular (RV) afterload, which eventually leads
to manifest right heart failure (RHF) and premature death.
Current available medical treatments aim to reduce RV after-
load, thereby secondarily improving RV function.1 No treatment
is currently available that improves RV function directly, par-
tially because it was not considered a therapeutic target in PH.2
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Recently, several reports have shown that sympathetic
activity is increased in patients with PH.3–7 Similar to left
heart failure (LHF), “ventricle-specific” down regulation of
1-adrenergic receptors was observed in RV samples of PH
patients.8 In addition, we recently demonstrated that exercise
training was detrimental in experimental and progressive
PH.9 The deleterious effects could be related to bouts of
exercise-induced sympathetic stimulation.
Although increased adrenergic activity is a compensatory
mechanism to maintain cardiac function by increasing con-
tractility and heart rate, it became apparent that chronic
adrenergic overactivity has, in the long run, detrimental
effects on cardiac function.10 This supports the use of
-adrenergic blockade in LHF management, which has been
demonstrated to significantly reduce mortality and left ven-
tricular (LV) remodeling.11
Nevertheless, and notwithstanding the substantial evidence
of their beneficial effects in LHF, the use of -blockers
currently is not recommended for patients with PH.1 PH
patients are unable to increase stroke volume during exercise,
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and as a consequence they are presumed to be highly heart
rate dependent to raise cardiac output.12 Furthermore, in an
acute model of PH, it was demonstrated that right ventriculo-
arterial uncoupling occurs after intravenous -blocker
administration.13
However, the -blockers used in these studies were first
generation unselective -blockers,13,14 with more bronchial
and vascular side effects.10 In addition, the dosages used in
these studies were relatively high, whereas a low dose could
have sufficed and been tolerated better. Furthermore, no data
are available on the long-term effects of -adrenergic recep-
tor blockade in PH patients. This aspect is important, as the
typical time course of improvement by -blockers in LHF is
preceded by initial functional decline, with significant clinical
improvement not to be expected before 3 months after start of
therapy.15
Recently, Bogaard and coworkers16 provided some hemo-
dynamic and molecular insights in effects of carvedilol (an
unselective -blocker) in PH rats. However, in the absence of
load independent measurements of RV function, it is unclear
whether the beneficial effects are RV-specific or related to the
1-associated pulmonary vascular effects of carvedilol.17 In
addition, it remains uncertain whether -blockers can restore
-adrenergic receptor (AR) signaling and delay progression
of right heart failure. In the present study, we therefore (1)
assessed the chronic effect of bisoprolol (a cardio-selective
-blocker) on disease progression by sequential echocardio-
graphic measurements, (2) evaluated RV function using load
independent parameters derived from pressure-volume anal-
yses, and (3) studied the AR- signaling, assessing its direct
downstream targets.
Methods
All experiments were approved by the Institutional Animal Care and
Use Committee of the VU University, Amsterdam, The Netherlands.
Male Wistar rats were used (150 to 175 g, 30 in total), and
experimental PH was induced by monocrotaline (60 mg/kg).9,18
Part I: Dose Finding by Pressure Telemetry
The minimal effective dose of bisoprolol that could blunt heart rate
response during daily activity (10%) was determined by telemetry
(TA11PA-C40, Data Science International [DSI], St. Paul, MN).19
Ten days after PH induction, bisoprolol was given once daily for 3
consecutive days by oral gavage, at start of their active phase (ie,
night: 18:00 to 06:00 hours); 4 PH rats received 5 mg/kg bisoprolol
once daily and the other 4 received 10 mg/kg. The effect of
bisoprolol on heart rate, systemic blood pressure, and physical
activity were evaluated (for details, see the online-only supplement).
Part II: “Clinical” Effects of Bisoprolol Treatment
in Experimental PH
In the second part of the study, 22 rats were included (no telemetry):
8 control rats and 14 rats treated with monocrotaline. Ten days after
PH induction, PH rats were randomized for bisoprolol treatment
(PHbiso; 10 mg/kg) or vehicle/water (PH) by oral gavage (n7/
group). Rats were treated for maximally 3 weeks (day 10 until day
31). Rats that showed clinical signs of manifest RHF (defined as
5% loss in body mass or respiratory distress, cyanosis, lethargy)
were euthanized earlier, in keeping with the protocol approved by the
Institutional Animal Care and Use Committee. Manifest RHF was a
survival end point and recorded as an event in the survival analyses.9
Hemodynamic Evaluation
Rats were evaluated by echocardiography 10 days after (monocro-
taline) injection and at end of study (when manifest RHF developed,
or 31 days after injection).9,19 At end of study, open-chest RV
catheterization (Millar Instruments, Houston, TX) was performed
under general anesthesia in all rats (isoflurane induction: 4.0% in 1:1
O2/air mix; maintenance: 2.0% in 1:1 O2/air mix; see the online-only
supplement).9 Noninvasive estimations of disease progression and
RV wall stress are described in the online-only supplement.
Using custom made algorithms (programmed in MATLAB 2007b,
The MathWorks, Natick, MA) RV (peak-) systolic pressures and RV
end-diastolic pressures were automatically determined from steady
state measurements, as well as arterial elastance (Ea), a measure for
RV afterload.13,20 From occlusion data, end-systolic elastance (Ees;
contractility) and end-diastolic elastance (Eed; filling) were deter-
mined.20,21 These parameters represent the slope of the end-systolic
and end-diastolic pressure-volume relationships, respectively, and
are considered load independent measures for cardiac contractility
(Ees) and filling (Eed).20,22 In addition, we calculated the preload
recruitable stroke work and the dP/dtmax end-diastolic volume
relation to assess RV contractile performance.23 The ratio Ees/Ea
was calculated as an estimate for ventriculo-arterial coupling (car-
diac adaptation in relation to its load).13,20
Histomorphology of Heart and Lungs
After the final hemodynamic assessment, all 22 rats were euthanized
(by exsanguination under isoflurane), and heart, lungs, and other
major organs were harvested. Cardiomyocyte cross-sectional area,
cardiac fibrosis, relative wall thickness of pulmonary arterioles,
myocardial capillary density (using CD31-antibodies), and myocar-
dial inflammation (using CD45-antibodies) were determined (see the
online-only supplement).9,24
Protein Analyses -Adrenergic Signaling
Phosphorylation of cardiac myosin binding protein C (cMyBPC) and
cardiac troponine I (cTnI) was determined as described before.25 All
RV samples were treated with trichloroacetic acid, to preserve
phosphorylation of cMyBPC and cTnI. Samples were separated on a
gradient gel (Criterion Tric-HCL 4% to 15% gel, Bio-Rad Labora-
tories, Berkeley, CA), and proteins were stained for 1 hour with
ProQ Diamond Phosphoprotein Stain (Molecular Probes, Eugene,
OR). Fixation, washing, and destaining were performed according to
manufacturers’ guidelines. Subsequently, gels were stained with
SYPRO Ruby staining (Molecular Probes) for determination of total
protein levels of cMyBPC and cTnI. The phosphorylation status of
cMyBPC and cTnI was expressed relative to total protein levels to
correct for differences in sample loading.
Statistical Analysis
All analyses were performed in a blinded fashion. All data were
verified for normal distribution. Data are presented as meanSEM.
A probability value 0.05 was considered statistically significant.
Comparison of telemetric registrations of PH rats before/after
bisoprolol treatment was performed by 2-way ANOVA for repeated
measurements, and the interaction between bisoprolol treatment and
time was tested and reported. One-way ANOVA was used for the
analyses of disease progression, pressure-volume relation, autopsy
data, and protein analyses, with Bonferroni posthoc comparison
between PH rats with/without bisoprolol treatment. Survival esti-
mates were performed by Kaplan-Meier analysis, with posthoc
comparison performed by log rank (Mantel-Cox) test between PH
rats with/without bisoprolol treatment (SPSS 16.0 for Windows,
SPSS, Chicago, IL).
Histological data were analyzed using multilevel analysis to
correct for nonindependence of successive measurements per animal
(MLwiN 2.02.03, Center for Multilevel Modeling, Bristol, UK).9,24
Results
Part I: Minimal Effective Dose of Bisoprolol in
PH Rats
Echocardiography confirmed the PH status of all 8 rats at day
of bisoprolol administration (reduced pulmonary artery ac-
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celeration time/cl, increased RV wall thickness). Only 10
mg/kg was able to completely blunt heart rate response
during daily activity completely (Figure 1A). At this dose,
systemic blood pressure and physical activity were minimally
affected, which indicates that this dosage was well tolerated
by PH rats (Figures 1B and C).
Part II: Effects of 10 mg/kg Bisoprolol in
Established PH
Bisoprolol Delayed the Progression Toward Right
Heart Failure
In a separate group of rats, we determined PH status 10 days
after (monocrotaline) injection, by echocardiography, right
heart catheterization, and histomorphology. Monocrotaline-
treated rats (n5) revealed lower PAAT/cl, indicating higher
RV systolic pressure9 and higher RV wall thickness, indicat-
ing (moderate) RV hypertrophy (Table S1; see the online-
only supplement). In addition, increased RV systolic pres-
sures, pulmonary vascular remodeling, and RV hypertrophy
at day 10 were confirmed by RV catheterization and histo-
morphometric analyses (Tables S1 and S2; see the online-
only supplement). The PH state before start of bisoprolol
treatment, thereby, was confirmed in all monocrotaline-
treated rats. Compared with vehicle-treated PH rats, biso-
prolol delayed the time to manifest RHF, as defined in the
Methods section (Figure 2). This finding was confirmed by
serial echocardiography, demonstrating that bisoprolol signif-
icantly delayed the progression of RV dilatation and reduced
the decline in cardiac function, whether measured by tricus-
pid annular plane systolic excursion or cardiac output (Figure
3; Table S3 [see the online-only supplement]; P0.05).
Preservation of cardiac output was mainly the result of an
increase in stroke volume rather than increased heart rate.
At end of study, cardiac function was maintained partially
by bisoprolol treatment (tricuspid annular plane systolic
excursion, control: 4.00.1; PH: 1.40.1; PHbiso
2.40.2 mm, PH versus PHbiso: P0.001; cardiac output,
control: 882.1; PH 171.6; PHbiso: 341.9 mL/min, PH
versus PHbiso: P0.001; Figures 3D and E). No differ-
ences were observed in RV wall thickness and RV dilatation
between bisoprolol- and vehicle-treated PH rats (Figures 3B
and C). In addition, end-systolic wall stress was similar in
bisoprolol- and vehicle-treated PH rats (RV end-systolic
wall stress, control: 805; PH: 33626; PHbiso: 308
14 mm Hg; PH versus PHbiso: P0.26).
Bisoprolol Improved Cardiac Function, Without
Affecting RV Afterload
Right ventricular pressure-volume measurements at end of
study (Figures 4A–C) revealed that RV systolic pressures
were significantly elevated in PH rats compared with control,
but no difference was found between bisoprolol- and vehicle-
treated PH rats (Figure 4D), which is in line with previous
echo findings (Figures 3A and B). Ea (measure of vascular
resistance) was elevated also in PH, but again, no difference
was observed between bisoprolol- and vehicle-treated PH rats
(Figure 4E). This indicates that bisoprolol treatment did not
affect RV afterload. We also found an equal rise in (wet) lung
mass observed at autopsy, and comparable remodeling of the
pulmonary arteries during histological examination (Tables
S4 and S5; see the online-only supplement).
On the other hand, bisoprolol treatment increased Ees
(measure of contractility; Figure 4F), resulting in partial
normalization of the ventriculo-arterial coupling (Ees/Ea;
Figure 4G). Preload recruitable stroke work (control:
21135, PH: 1362156, PHbiso: 2161312 mm Hg; PH
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Figure 1. Averaged 24-hour registration of PH rats before and after treatment of 10 mg/kg bisoprolol. This dosage was able to com-
pletely blunt heart rate response during the whole active phase (between 18:00 and 06:00 hours) of the rats (A: gray area). In addition,
only a moderate effect on systemic blood pressure was observed (B), without an (adverse) effect on daily physical activity (C). Data pre-
sented as mean SEM, n4 (PH/PHbiso). Probability values represent interactive term (time*treatment). PH (solid/red line) indicates
vehicle-treated PH rats; PHbiso (dotted/blue line), bisoprolol-treated PH rats.
Figure 2. Bisoprolol treatment in PH significantly delayed time
to manifest right heart failure. Log rank test: X24.54; P0.05.
Control: n8; PH/PHbiso: n7. * indicates P0.05 PHbiso
versus PH.
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versus PHbiso: P0.001) and dP/dtmax end-diastolic vol-
ume (dP/dtmax-EDV) relation showed similar results (con-
trol: 3.70.6, PH: 11.12.7, PHbiso: 23.35.7 mm Hg/
ms/mL; PH versus PHbiso: P0.001). Of note, after
normalization of Ees for RV mass,26 no significant difference
was observed anymore between vehicle-treated PH rats and
controls, whereas the difference in contractility between
bisoprolol- and vehicle-treated PH rats remained statistically
significant (Ees/RVmass, control: 40.36.3, PH: 43.612.0,
PHbiso: 99.010.9 mm Hg/mL/g; P0.02 PHbiso ver-
sus PH). After normalization of Ees for RV volume, contrac-
tility was reduced significantly in vehicle-treated PH rats and
improved toward normal value in the bisoprolol-treated PH
rats (Ees/RVvolume, control: 2.140.13; PH: 1.320.08;
PHbiso: 2.280.14 mm Hg/mL2  103; PH versus
PHbiso: P0.001). Furthermore, bisoprolol treatment re-
duced RV end-diastolic pressures and Eed (measure of
filling; Figures 4H and I).
Bisoprolol Reduced RV Fibrosis and RV
Myocardial Inflammation
In line with previous echo findings, the right ventricles of PH
rats at end of study were hypertrophied compared with
controls (Figure 3B). No differences were observed between
bisoprolol- and vehicle-treated PH rats, whether expressed as
RV mass (irrespective of normalization), RV/(LVS) ratio,
or RV cardiomyocyte cross-sectional area (Tables S4 and S5;
see the online-only supplement).
At start of treatment, no difference was observed between
control and PH rats in RV capillary density or fibrosis, and
there were no signs of cardiac inflammation (Table S2; see
the online-only supplement). At end of study, the findings for
RV capillary density were similar; compared with control,
capillary density was reduced in PH, without a significant
difference between the 2 PH groups (Figure 5A, D, and G).
More RV interstitial fibrosis was observed between PH rats
and controls; interestingly, bisoprolol treatment significantly
reduced RV fibrosis (Figure 5B,E,and H). Furthermore, the
presence of (CD45) inflammatory cells in RV myocardium
of bisoprolol-treated PH rats was significantly less, compared
with vehicle-treated PH rats (Figure 5C, F, and I). Leukocyte
infiltration in the left ventricle was increased in bisoprolol-
and vehicle-treated PH rats; however, these values were low
and comparable with control values of the right ventricle
(Table S5; see the online-only supplement). Autopsy and
assessment of LV histology revealed no effect of bisoprolol
(Tables S4 and S5; see the online-only supplement), compat-
ible with a RV-specific effect of bisoprolol.
Bisoprolol Restored RV -Adrenergic Receptor
Signaling Pathway
Phosphorylation of both cMyBPC and cTnI (protein kinase
A-mediated downstream targets of the AR) were signifi-
cantly higher in bisoprolol-treated PH rats in comparison with
vehicle-treated PH rats (Figure 6).
Discussion
This study investigated the effects of bisoprolol treatment in
experimental PH, focusing on RV function and remodeling.
Using a comprehensive set of physiological and pathological
end points, we have demonstrated that:
1. Chronic low-dosed bisoprolol treatment was well toler-
ated, and delayed time to manifest RHF.
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Figure 3. Disease progression during treatment period. Echocardiography could confirm the PH status at start of treatment (A, B: first time
point, lower pulmonary artery acceleration time/cl and higher RV wall thickness). Bisoprolol treatment (PHbiso: dotted/blue) delayed RV dila-
tation (C, arrow) and reduced the decline in cardiac function (D, E: arrows), compared with vehicle-treated PH rats (PH: solid/red); numeric
data are found in Table S1 (see the online-only supplement). In addition, at end of study cardiac function was better maintained in bisoprolol-
treated PH rats. Data presented as meanSEM, control: n8; PH / PHbiso: n7. ### indicates P0.001 PH/PHbiso versus control; *,
P0.05, ***, P0.001 PHbiso versus PH. PAAT/cl indicates pulmonary artery acceleration time normalized for cardiac cycle length
(inversely correlated with RV systolic pressure); RVEDD, RV end-diastolic diameter; TAPSE, tricuspid annular plane systolic excursion.
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2. Bisoprolol treatment improved cardiac function by im-
proving RV contractility (Ees), filling (Eed), and
ventriculo-arterial coupling (Ees/Ea).
3. The cardiac-selective effects of bisoprolol can be attrib-
uted to restoration of RV -adrenergic receptor signal-
ing, the reduction of RV (interstitial) fibrosis, and RV
myocardial inflammation.
These results suggest a potential role for -blocker in PH
that warrants further clinical investigation.
Bisoprolol Treatment Was Well Tolerated
Beta-blockers are currently not recommended, because PH
patients are believed not to tolerate the acute (but transient)
negative inotropic and chronotropic effects.1,13,14 To address
this legitimate argument, we used an approach that was
inspired by successful -blocker use in LHF.
Low Versus High Dose
By definition, patients with LHF are hemodynamically com-
promised, and like in PH, their adrenergic system is overac-
tivated as well.27 To some extent, these 2 patient groups are
therefore comparable.3 Interestingly, most LHF patients (ap-
proximately 85%) enrolled in clinical trials with -blockers
were able to tolerate short- and long-term treatments with this
drug, and reached the maximum planned target dose, when
-blockers are introduced at a very low dose, followed by
gradual dosage increase (“start low, go slow”).11 In addi-
tion, whereas the adverse effects of -blockers are dose
dependent, the beneficial effects are associated with heart
rate reduction, which can be achieved by lower dosages.28
In this study, we used the minimum dose that effectively
blunted heart rate response. This was accompanied by only
minimal side effects, and was therefore well tolerated by
the PH rats (minor effect on blood pressure, no effect on
activity). Compared with other rat studies that used biso-
Control
0
50
100
0.1
Rel. volume (ml)
Pr
es
su
re
 (m
m
H
g)
PH
0
50
100
0.1
Rel.volume (ml)  
Pr
es
su
re
 (m
m
H
g)
PH+biso
0
50
100
0.1
Rel.volume (ml)
Pr
es
su
re
 (m
m
H
g)
RV SP
Control PH PH+biso
0
50
100 n.s.
(m
m
Hg
)
RV EDP
Control PH PH+biso
0.0
2.0
4.0
6.0
8.0 **
(m
m
Hg
)
Ea
Control PH PH+biso
0
500
1000
1500
n.s.
(m
m
Hg
/m
l)
Ees
Control PH PH+biso
0
500
1000 ***
(m
m
Hg
/m
l)
Eed
Control PH PH+biso
0
20
40
60 **
(m
m
Hg
/m
l)
Ees/Ea
Control PH PH+biso
0.0
0.5
1.0
1.5
*
A B C
D E F
G H I
Figure 4. Pressure-volume analyses. Typical examples of the pressure-volume relation are shown for control, PH, and PHbiso (A, B,
and C: line indicates end-systolic pressure-volume relationship). RV systolic pressures (RVSP) and arterial elastance (Ea; measure of RV
afterload) were increased equally in both PH groups (D, E). However, RV contractility (end-systolic elastance [Ees]) was increased sig-
nificantly by bisoprolol treatment (F), resulting in partial normalization of ventriculo-arterial coupling (Ees/Ea; G). Bisoprolol treatment
also partially restored RV diastolic function, measured by RV end-diastolic pressure (RVEDP) and Eed (H, I). Control: n8,
PH/PHbiso, n7. * indicates P0.05; **, P0.01; ***, P0.001; PHbiso versus PH.
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prolol (typically 60 mg/kg), the dose used in this study can
be considered low.29
Hemodynamic data at day 10 suggests limited functional
hemodynamic compromise of the PH rats at start of treat-
ment. Unfortunately, the progressiveness of the model did not
permit starting treatment at a later time point. However, like
in LHF,11 -blocker use most likely will be limited to PH
patients with some cardiac reserve, in order to cope with its
acute negative inotropic effects.
Selective Versus Unselective -Blocker
Of all -blockers, only bisoprolol, carvedilol, and metoprolol
have been proven to reduce mortality in LHF.11 Of these 3,
bisoprolol is the most 1-cardioselective.10 We chose biso-
prolol to avoid potential harmful effects of 2-mediated
blockade. The 2-subtype is the predominant AR present in
the pulmonary vasculature. Blockade of the 2-receptors may
lead to smooth muscle contraction, which could result in a
further increase in pulmonary vascular resistance and RV
pressures. Nevertheless, the clinical relevance of 1-
selectivity in PH is unknown.
Beneficial Effects of Bisoprolol
To ease the clinical interpretation of our findings, we used
robust and clinically relevant outcome measures to investi-
gate the effects of bisoprolol. We explicitly evaluated
pressure-volume relations, because it is considered the gold
standard to describe cardiac function,20,26 and more specifi-
cally, to address the potential risk of ventriculo-arterial
uncoupling after -blocker use in PH, as raised by others.13 In
contrast to what was feared, we observed partial normaliza-
tion of the ventriculo-arterial coupling, which may be ex-
plained by chronic opposed to acute drug administration.
Measurements of RV wall thickness and diastolic diameter
at end of study protocol failed to detect changes that could
explain the beneficial effects of bisoprolol. However, it
should be noted that these measurements were obtained at a
stage of terminal right heart failure, which was reached at a
later time point in the bisoprolol-treated PH group than the
PH control group: eg, the progression of RV dilatation was
significantly less in the bisoprolol-treated rats (Figure 3C: RV
end-diastolic diameter; Table S3 [see the online-only supple-
ment]). Hence, the beneficial effect of bisoprolol between
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Figure 5. Bisoprolol treatment reduced RV fibrosis and RV myocardial inflammation. Histomorphometric analyses revealed significant
and selective reduction of RV interstitial fibrosis and RV myocardial inflammation in bisoprolol-treated PH rats (B, C). No difference was
observed for RV capillary density (A). Typical examples are shown of histological sections of the right ventricle of vehicle- (PH: D, E,
and F) and bisoprolol-treated PH rats (PHbiso: G, H, and I), stained for RV capillarization (D, G: endothelium marker CD31 is stained
green, cell membranes red; capillaries appear as small yellow/orange dots), fibrosis (E, H: picrosirius red staining, dark gray), and infil-
trating inflammatory cells (F, I: lymphocyte marker CD45 is stained green, cell membranes red, nuclei blue). Control: n8; PH/PHbiso:
n7. *indicates P0.05 PHbiso versus PH.
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both groups are reflected more by the time elapsed to reach
right heart failure than the hemodynamic findings at right
heart failure. In addition, we observed less RV inflammation
and fibrosis, together with an increase in RV contractility
normalized for hypertrophy (Ees/RVmass), in the bisoprolol-
treated PH group compared with the control PH group. This
implies that bisoprolol treatment results in improved intrinsic
properties of RV cardiomyocytes that cannot be detected by
relatively crude measures such as RV wall thickness and
diastolic diameters.
Only a few studies have evaluated the (chronic) effects of
-blockers in the context of PH.14 A recent paper by Bogaard
et al16 provides some hemodynamic and molecular insights in
the effects of carvedilol (a nonspecific 1/1/2-adrenergic
receptor blocker) on echocardiographic parameters and mo-
lecular analyses in PH rats. For the first time, we demonstrate
that the positive effects of -blocker treatment are RV-
specific and could delay disease progression, improve RV
function, and (partially) restore ventriculo-arterial coupling
and AR-signaling. Bogaard et al16 also observed less RV
fibrosis after -blocker treatment. They found an increase in
RV capillary density, which we could not confirm. We, on the
other hand, observed a reduction in RV inflammation, which
was not studied in detail by Bogaard et al.16 Differential
effects of the -blockers used might explain these subtle
differences. An alternative explanation is related to differ-
ences in disease severity of the experimental models used; in
our monocrotalin model, all rats developed right heart failure
within 4 weeks, whereas all hypoxia/Sugen rats survived 8
weeks after induction of PH. As a consequence, treatment
duration in our monocrotaline model was relatively short
(median treatment was 2.5 weeks) compared with Bogaard’s
Sugen/hypoxia model (4 weeks).16 It is possible that biso-
prolol treatment reduced RV inflammation and RV fibrosis
(early effects), but that its treatment duration was insufficient
to enhance RV capillary density (late effect). Usui et al30 also
investigated the effect of carvedilol in monocrotaline-treated
rats. They too observed survival benefit with -blocker, but
unfortunately they did not report any measures on cardiac
function, and focused mainly on LV rather than RV remod-
eling. Also, no information was provided on possible side
effects and tolerability. In addition, Ishikawa et al31 reported
beneficial effects of arotinolol (a nonspecific -blocker)
using the same PH rat model. However, the clinical implica-
tions of this study are limited; arotinolol was studied to
prevent rather than to treat PH-associated RHF, and, unlike
bisoprolol, arotinolol is not clinically used or Food and Drug
Administration approved.
Potential Mechanisms
In this proof of concept study, we did not perform in-depth
analysis on cellular and molecular effects of bisoprolol.
Nonetheless, our histological and protein analysis may pro-
vide some mechanistic insights, based on the experiences
with -blockers in LHF.
Although the -adrenergic system in LHF is incompletely
understood, it is generally believed to exert its beneficial
effects by blunting of the sympathetic overactivity, resulting
in reduced desensitization of the AR and restoration of
AR-signaling.32 Protein kinase A is a central player in the
AR-signaling.33 Therefore, we investigated the effect of
bisoprolol on phosphorylation of contractile proteins
cMyBPC and cTnI, 2 main targets of protein kinase A.
Interestingly, we observed that bisoprolol restored phosphor-
ylation of both cMyBPC and cTnI, compared with vehicle
treatment. This suggests that bisoprolol restored RV cardio-
myocyte AR-signaling.
An alternative explanation for the observed beneficial
effects of bisoprolol therapy might be that a reduction in heart
rate by -blockers could have prevented sustained high levels
of RV wall stress. We previously observed that exercise
increased myocardial inflammation in experimental PH, and
related this to increased RV wall stress during episodes of
activity,9 comparable with what has been described in detail
by Sun et al.34 This is in agreement with the observation of
the present study that bisoprolol prevents rather than reverses
RV inflammation, as no inflammation was observed at start
of treatment, which also argues against direct cardiac inflam-
matory effects of monocrotaline.
Figure 6. Bisoprolol treatment restored
-adrenergic receptor signaling. A typical
example of a pro-Q/SYPRO gel is shown
for control, vehicle-treated, and
bisoprolol-treated PH rats. Analyses
revealed increased phosphorylation of
downstream AR-targets myosin binding
protein C (cMyBPC) and troponin I (cTnI)
after bisoprolol treatment. Control: n8;
PH/PHbiso: n7. * indicates P0.05
PHbiso versus PH.
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Clinical Relevance
We demonstrated that -blocker therapy is beneficial in
experimental PH. However, the monocrotaline model exhib-
its alterations in the -adrenergic system that resemble those
in human PH; others have previously demonstrated that in
monocrotaline-treated rats with RHF, heart rate variability is
reduced,35 plasma norepinephrine levels are increased, and
1-adrenergic receptor density of the right ventricle is de-
creased,36 similar to clinical PH.3
Despite bisoprolol treatment all PH rats eventually devel-
oped right heart failure. However, we want to emphasize that
the effects of bisoprolol were achieved in the absence of
“traditional” vasodilating therapies (eg, bosentan) that mod-
ulate the progression of pulmonary vascular remodeling. The
findings of this study therefore provide a rationale to inves-
tigate the role of (cardioselective) -blockers as an add-on
therapy in the management of clinical PH.
Conclusions
In our PH rat model, bisoprolol treatment was well tolerated
and beneficial. It delayed the progression toward RHF, which
was attributed to improved RV contractility and compliance,
and was accompanied by restored -adrenergic receptor
signaling and reduced RV fibrosis and inflammation. Future
studies are necessary to address the clinical implications of
our findings.
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CLINICAL PERSPECTIVE
The use of beta-blockers is presently contraindicated in the clinical management of patients with pulmonary arterial
hypertension (PH). Increased sympathetic activity is believed to be a compensatory mechanism to maintain cardiac output
by increasing heart rate and right ventricular (RV) contractility. However, as has been shown for left heart failure, chronic
adrenergic overstimulation might be detrimental in the long run. In the present study, we therefore studied the chronic
effects of a cardio-selective -blocker (bisoprolol) on disease progression, RV function, and -adrenergic signaling. In our
PH rat model, bisoprolol treatment was well tolerated and beneficial; it delayed the progression towards right heart failure,
which was attributed to improved RV contractility and compliance, and was accompanied by restored -adrenergic
receptor signaling and reduced RV fibrosis and inflammation. These findings provide a rationale to investigate the clinical
application of -blockers in PAH. However, the acute negative inotropic effects of -blockers on the pressure overloaded
right ventricle necessitates a very careful approach. For that reason, we are currently conducting a prospective clinical study
to evaluate whether a cautious introduction of -blockers in New York Heart Association II/III PAH patients is tolerated
and safe.
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